The rising prevalence and changing age distribution of multiple sclerosis in Manitoba
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Several studies suggest an increasing prevalence of multiple sclerosis (MS) in Canada. We aimed to validate a case definition for MS using administrative health insurance data, and to describe the incidence and prevalence of MS in Manitoba, Canada.
Methods: We used provincial administrative claims data to identify persons with demyelinating disease using International Classification of Diseases 9/10 codes and prescription claims. To validate the case definition, questionnaires were mailed to 2,000 randomly selected persons with an encounter for demyelinating disease, requesting permission for medical records review. We used diagnoses abstracted from medical records as the gold standard to evaluate candidate case definitions using administrative data.
Results: From 1984 to 1997, cases of MS using claims data were defined as persons with ≥7 medical contacts for MS. From 1998 onward, cases were defined as persons with ≥3 medical contacts. As compared to medical records, this definition had a positive predictive value of 80.5% and negative predictive value of 75.5%. From 1998 to 2006, the average age- and sex-adjusted annual incidence of MS per 100,000 population was 11.4 (95% confidence interval [CI] 10.7–12.0). The age-adjusted prevalence of MS per 100,000 population increased from 32.6 (95% CI 29.4–35.8) in 1984 to 226.7 (95% CI 218.1–235.3) in 2006, with the peak prevalence shifting to older age groups.
Conclusion: The prevalence of multiple sclerosis (MS) in Manitoba is among the highest in the world. The rising prevalence with minimally changing incidence suggests improving survival. This study supports the use of administrative data to develop case definitions and further define the epidemiology of MS.
Glossary
- CI=
- confidence interval;
- DIN=
- drug identification number;
- DPIN=
- Drug Programs Information Network;
- ICD=
- International Classification of Diseases;
- MHHL=
- Manitoba Health and Healthy Living;
- MS=
- multiple sclerosis.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Incidence and prevalence of MS in childrenA population-based study in Ontario, CanadaRuth Ann Marrie, Julia O'Mahony, Colleen Maxwell et al.Neurology, September 26, 2018 -
Review
Lower prevalence of multiple sclerosis in First Nations CanadiansRuth Ann Marrie, Stella Leung, Nancy Yu et al.Neurology: Clinical Practice, January 23, 2018 -
Article
Sex differences in comorbidity at diagnosis of multiple sclerosisA population-based studyRuth Ann Marrie, Scott B. Patten, Helen Tremlett et al.Neurology, March 09, 2016 -
Views & Reviews
A new way to estimate neurologic disease prevalence in the United StatesIllustrated with MSLorene M. Nelson, Mitchell T. Wallin, Ruth Ann Marrie et al.Neurology, February 15, 2019